NYSE · Healthcare · Medical Devices · USA
Abbott Laboratories is a large cap company (market value between $10 billion and $200 billion) in the Medical Devices industry.
Abbott Laboratories discovers, develops, manufactures, and sells a broad range of healthcare products organized into four business lines: branded generic drugs, diagnostic systems and tests, nutritional products for infants and adults, and cardiovascular and neuromodulation devices. The company distributes these products worldwide to wholesalers, hospitals, retailers, government agencies, and healthcare facilities.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Abbott Laboratories stock.
Overvalued: intrinsic value $69.62 per share, market price $104.06, margin of safety -49.5% (as of 2026-10-19).
Discounting its cash flows at 8.3% (average of 3 methods) values the shares at $69.62; the price of $104.06 is 49% above that value, and 78% of that value comes from beyond year five.
Leak Score: 56/100 on 12 of 12 signals (Weak Signal).
17 more funds hold it; the full list is part of the paid plan.
All 142 Medical Devices stocks
27 more in this industry show a wider margin of safety.
ABT is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 8.3% (average of 3 methods) values the shares at $69.62; the price of $104.06 is 49% above that value, and 78% of that value comes from beyond year five.
$69.62 per share (as of the 2026-10-19 close), against a market price of $104.06. That is a margin of safety of -49.5%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
The price asks for more growth than the company has delivered. It needs the future to beat the past. Yearly sales growth the price needs: 19.3%. Yearly sales growth it has sustained: 4.6%.
56 out of 100, which we rate "Weak Signal", on 12 of 12 value investing signals.